IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 2, September 2025

Impact Factor: 7.67

Quality Risk Management and Process Control

Ms. Komal Naresh Aher, Dr. Sachin Vitthal Datkhile, Mr. Omkar Rajaram Gosavi
Ms. Divya Shivaji Deshmukh, Ms. Bhakti Santosh Gurav
Department of Pharmaceutical Quality Assurance
Samarth Institute of Pharmacy Belhe, Pune, Maharashtra, India
Corresponding Author: Ms. Komal Naresh Aher
aherkomal351@gmail.com

Abstract: *Quality Risk Management (QRM) is a systematic process for identifying, evaluating, and controlling risks to product quality and patient safety in compliance with regulatory standards such as ICH Q9. In the pharmaceutical industry, QRM is essential for decision-making, process optimization, and maintaining regulatory compliance. However, its practical implementation faces several challenges, including inadequate training, inconsistent application across departments, insufficient and unreliable data, subjective risk scoring, and limited integration with Quality Management Systems (QMS). Organizational resistance, resource constraints, and varying expectations of global regulatory agencies further complicate the process. These issues can result in incomplete risk assessments, delayed mitigation measures, and reduced overall effectiveness of QRM frameworks. Addressing these challenges requires strong management commitment, harmonized procedures, regular training, and effective integration of QRM with QMS elements such as CAPA, deviation management, and change control. A proactive, data-driven, and continuously reviewed QRM system can transform risk management from a regulatory obligation into a strategic tool for quality improvement, efficiency, and patient safety. This review highlights key barriers in QRM and emphasizes the importance of targeted strategies to enhance its effectiveness and long-term sustainability in pharmaceutical quality assurance*

Keywords*:* Quality Risk Management, QRM challenges, pharmaceutical quality, ICH Q9, risk assessment, process control, quality management system, patient safety

I. INTRODUCTION

Quality Risk Management (QRM) and Process Control are integral components of modern pharmaceutical quality systems, aimed at ensuring that products consistently meet predefined quality standards. With the growing complexity of manufacturing processes, regulatory agencies such as the International Council for Harmonisation (ICH) have emphasized the systematic application of risk management principles, as outlined in ICH Q9, to identify, evaluate, and control potential quality risks throughout a product's lifecycle. QRM is a structured approach that involves the assessment of potential hazards, the estimation of their likelihood and severity, and the implementation of strategies to minimize their impact. It enables manufacturers to prioritize resources on high-risk areas, thus enhancing efficiency and reducing the probability of failures. Common tools used in QRM include Failure Mode and Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and Fault Tree Analysis (FTA). Process control, on the other hand, focuses on maintaining manufacturing parameters within established limits to ensure consistent output quality. This includes real-time monitoring of critical process parameters (CPPs) and critical quality attributes (CQAs) using advanced control systems. Statistical Process Control (SPC), feedback and feed forward controls, and automation technologies play a significant role in reducing process variability.

When effectively integrated, QRM and process control form a robust framework for proactive decision-making, continuous improvement, and compliance with current Good Manufacturing Practices (cGMP). These practices not only safeguard patient safety but also contribute to cost efficiency, reduced waste, and higher product reliability.

The aim of this review is to provide a comprehensive understanding of QRM principles, process control strategies, and their synergistic role in ensuring high-quality pharmaceutical products. It also highlights current industry challenges,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

evolving regulatory expectations, and the importance of continuous monitoring and improvement for long-term success in pharmaceutical manufacturing.

In the pharmaceutical industry, ensuring that every batch of medicine is safe, effective, and of high quality is not just a regulatory requirement—it is a moral responsibility. Quality Risk Management (QRM) and Process Control are two interlinked pillars that make this possible. Together, they provide a structured, scientific, and proactive approach to preventing quality failures before they occur, rather than reacting to them afterward.

QRM, as defined by ICH Q9 guidelines, is a systematic process for assessing, controlling, communicating, and reviewing risks to product quality throughout its lifecycle—from raw material sourcing to final distribution. This risk-based thinking allows manufacturers to identify which processes, materials, or operational steps have the highest potential to affect safety, efficacy, or compliance. Methods like Failure Mode and Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and Fault Tree Analysis (FTA) help quantify and prioritize these risks.

On the other hand, Process Control focuses on maintaining critical process parameters (CPPs) within acceptable ranges to ensure critical quality attributes (CQAs) remain consistent. This includes both manual and automated control strategies such as Statistical Process Control (SPC), real-time monitoring, and feedback/feedforward control systems. Process Analytical Technology (PAT) plays a vital role by enabling real-time measurements that support immediate corrective actions.

The integration of QRM with Process Control creates a robust quality framework that aligns with current Good Manufacturing Practices (cGMP) and regulatory expectations from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This integration not only safeguards patient health but also improves operational efficiency, reduces production costs, minimizes recalls, and strengthens market reputation.

This review aims to explore the principles, tools, and applications of QRM and Process Control, highlighting how their synergy ensures pharmaceutical manufacturing remains reliable, compliant, and continuously improving in a competitive global market.

Quality Risk Management

Defination:

Quality Risk Management is a systematic process for the assessment, control, communication, and review of risks to the quality of a pharmaceutical product throughout its lifecycle.It ensures that risks are identified, evaluated, and managed in a science-based and patient-focused manner.

Key points in definition:

- Systematic and documented approach.
- Applies to all stages of a product's lifecycle.
- Focuses on patient safety, product quality, and regulatory compliance.
- Uses scientific evidence and process understanding for decision-making.

Objectives

- Identify and understand potential risks that can affect product quality.
- Minimize or eliminate these risks through preventive measures.
- Prioritize resources to focus on high-risk areas.
- Support regulatory decision-making and compliance.

Principles of Quality risk management process:

The principles of Quality Risk Management are derived from the ICH Q9 guideline and focus on ensuring patient safety while maintaining product quality throughout the pharmaceutical product lifecycle.

The first and most important principle is that the evaluation of risk should be based on scientific knowledge and ultimately linked to the protection of the patient. Any potential risk to the quality, safety, or efficacy of the product must be identified, assessed, and controlled using data-driven and process-based decisions.

The second principle is proportionality — the level of effort, formality, and documentation in risk management activities should be commensurate with the level of risk. Low-risk issues require simpler control measures, while high-risk situations demand more detailed assessments and strict controls.

Another principle is transparency and communication. Risk-related decisions should be documented and communicated effectively to all stakeholders, including regulatory agencies when necessary.

Finally, QRM should be a continuous process applied across the entire product lifecycle — from development, manufacturing, and distribution to post-market monitoring. Regular review ensures that risk controls remain effective and relevant in light of changes in process, equipment, regulations, or scientific understanding.

Quality risk management process (ICH Q9)



The QRM process consists of four main steps :

The QRM process is a structured, systematic approach to identifying, assessing, controlling, communicating, and reviewing risks to product quality throughout its lifecycle. It consists of four main stages.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

1. Risk Assessment – Identify and understand the risk
Risk assessment is the foundation of QRM and includes three sub-steps:
1. Risk Identification – Recognizing potential hazards that may affect product quality, safety, or efficacy. Examples: contamination, equipment failure, raw material variability, human error.
2. Risk Analysis – Evaluating the nature of the risk by estimating probability, severity, and detectability.
3. Risk Evaluation – Comparing analyzed risks against pre-defined acceptance criteria to decide if action is needed.
Common Tools:

- Failure Mode and Effects Analysis (FMEA)
- Fault Tree Analysis (FTA)
- Hazard Analysis and Critical Control Points (HACCP)

2. Risk Control – Reduce or accept the risk
This step involves:

- Risk Reduction – Implementing measures to lower risk to an acceptable level (e.g., SOP updates, process automation, additional testing).
- Risk Acceptance – When risk is within acceptable limits and further reduction is not feasible.

3. Risk Communication – Share findings

- Relevant risk information is communicated between all stakeholders, such as Quality Assurance, Production, Engineering, and Regulatory bodies. Effective communication ensures everyone understands risk decisions and controls.

4. Risk Review – Monitor and improve
Risks and control measures are periodically reviewed to ensure they remain effective. Reviews are triggered by:

- Process changes
- New technology
- Deviations or complaints
- Updated regulatory requirements

Outcome : The QRM process ensures that quality-related decisions are science-based, documented, and proactive, leading to better compliance, reduced failures, and improved patient safety.

Integration of Quality Risk Management and Process Control
The integration of Quality Risk Management (QRM) and Process Control is essential for building a robust pharmaceutical manufacturing system that ensures product quality, regulatory compliance, and patient safety. While QRM focuses on identifying, assessing, and managing risks, Process Control ensures that manufacturing operations remain within validated parameters to consistently produce quality products.

1. Purpose of Integration
To link risk identification with real-time control measures.
To shift from a reactive approach (correcting defects after they occur) to a proactive approach (preventing defects before they occur).
To ensure that high-risk process parameters are continuously monitored and managed.

2. How QRM Supports Process Control
QRM identifies Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) during risk assessment.
It determines which process steps carry the highest risk and therefore require tighter control limits.
Risk ranking helps prioritize which processes need automation, additional sensors, or more frequent in-process testing.

3. How Process Control Supports QRM

Process control systems, such as Statistical Process Control (SPC), Process Analytical Technology (PAT), and real-time monitoring, provide data to verify if risk controls are effective.

Deviations detected by process control can trigger a risk review to reassess and improve control strategies.

Continuous monitoring ensures early detection of process drift, reducing the likelihood of deviations turning into product failures.

4. Benefits of Integration

- Consistency in product quality through real-time adjustments.
- Faster decision-making using live process data for risk-based actions.
- Reduced variability by controlling high-risk parameters more effectively.
- Regulatory compliance with ICH Q9, ICH Q10, and FDA's risk-based inspection approach.

5. Example in Practice

During tablet manufacturing, QRM may identify granulation moisture content as a critical risk for tablet hardness and dissolution. Process Control then ensures that moisture continuously monitored via sensors, with automated adjustments to drying time. This real time control directly addresses the risk identified in QRM .

Benefits of Quality Risk Management (QRM) and Process Control

The combined use of QRM and Process Control delivers significant advantages in pharmaceutical manufacturing, enhancing both product quality and operational efficiency.

1. Improved Product Quality and Patient Safety

- Risks affecting Critical Quality Attributes (CQAs) are identified early through QRM.
- Process Control maintains Critical Process Parameters (CPPs) within validated ranges, preventing variations that could harm product safety or efficacy.
- Early detection and control reduce the chances of substandard or unsafe products reaching patients.

2. Proactive Problem Prevention

- QRM emphasizes preventive action rather than corrective action.
- Process Control systems (e.g., PAT, SPC) provide real-time monitoring, enabling immediate adjustments before problems escalate.
- Minimizes batch failures and deviations by addressing root causes in real time.

3. Regulatory Compliance

Meets the expectations of ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System).

Supports FDA's risk-based inspection approach and EMA quality guidelines.

Well-documented risk management and control processes demonstrate regulatory readiness during audits.

4. Resource Optimization

- Focuses time, manpower, and budget on high-risk areas, avoiding unnecessary work in low-risk processes.
- Automation of high-risk process steps reduces human error and improves efficiency.
- Allows smarter allocation of quality monitoring resources.

5. Continuous Improvement

- Process Control generates valuable process performance data.
- QRM uses this data in risk reviews to refine control strategies and improve product quality over time.

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

- Supports a culture of continuous process verification in line with modern manufacturing principles

6. Reduced Costs from Failures and Recalls

- Early detection of issues prevents large-scale product failures.
- Reduces costs associated with rework, recalls, customer complaints, and regulatory penalties.
- Enhances brand reputation by consistently delivering safe, effective products.

7. Enhanced Decision-Making

- Risk-based thinking enables faster, science-backed decisions.
- Process Control provides real-time process data, supporting fact-based risk management.
- Improves cross-functional collaboration between Quality, Production, and Engineering teams.

Future Trends in Quality Risk Management (QRM)

As pharmaceutical manufacturing evolves, Quality Risk Management (QRM) is also advancing to meet the demands of regulatory changes, technological innovation, and industry best practices. Future trends focus on making QRM more predictive, data-driven, and integrated with modern manufacturing systems.

1. Digitalization and Automation in QRM

- Use of digital risk assessment platforms to replace manual, paper-based systems.
- Integration of QRM with Manufacturing Execution Systems (MES) and Enterprise Resource Planning (ERP) software for real-time risk tracking.
- Automated data capture from process control systems to feed directly into risk analysis.

2. Artificial Intelligence (AI) and Machine Learning (ML)

- AI-driven algorithms to predict potential risks before they occur by analyzing historical deviations, process trends, and environmental data.
- ML models to continuously improve risk prediction accuracy with each production cycle.
- AI-assisted decision-making for prioritizing mitigation actions.

3. Integration with Continuous Manufacturing

- QRM will be embedded into continuous manufacturing lines, where risks are managed in real time.
- Process Analytical Technology (PAT) tools combined with QRM for real-time quality assurance instead of end-product testing.

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

4. Real-Time Risk Monitoring

- Shift from static, periodic risk reviews to dynamic risk dashboards.
- Continuous monitoring of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) with automatic alerts when limits are approached.

5. Enhanced Regulatory Expectations

- Regulatory agencies (FDA, EMA, WHO) increasingly expect risk-based submissions and evidence of integrated QRM throughout the product lifecycle.
- Future inspections will focus more on data-driven risk control rather than documentation alone.

6. Predictive Quality Systems

- Using big data analytics from manufacturing, supply chain, and market performance to predict quality risks before they affect production.
- Linking QRM with post-market surveillance to identify risks emerging after product launch.

7. Holistic Lifecycle Risk Management

- QRM will not be limited to manufacturing; it will cover drug development, clinical trials, supply chain, distribution, and post-market monitoring.
- Stronger integration with Quality by Design (QbD) principles for end-to-end quality assurance.

Challenges in Quality Risk Management (QRM)

1. Lack of Clear Understanding and Awareness

- Many employees, especially in cross-functional teams, have limited training on QRM principles, terminology, and tools.
- Misinterpretation of concepts like risk identification, risk evaluation, and risk control can lead to inconsistent practices.
- Sometimes, QRM is seen as a regulatory formality instead of a proactive quality tool.

2. Inconsistent Implementation

- Different departments may apply different methods (e.g., some use FMEA, others use HACCP) without a unified standard.
- Lack of harmonized templates and procedures causes variability in risk assessments.
- Over-reliance on subjective judgments instead of data-driven decisions.

3. Insufficient Data for Risk Assessment

- Poor data collection systems or incomplete historical records lead to weak risk evaluations.
- Reliance on assumptions rather than evidence increases the possibility of incorrect risk ranking.
- Missing trend analysis due to ineffective process monitoring.

4. Cultural and Organizational Resistance

- Some teams view QRM as extra workload rather than a core quality responsibility.
- Senior management may not actively support or invest in robust QRM systems.
- Resistance to change from long-standing traditional practices.

5. Overcomplication of Risk Tools

- Using overly complex methods (e.g., detailed statistical models) when simpler tools could be more efficient.
- Excessive documentation that slows decision-making and delays project timelines.
- Difficulty in balancing scientific rigor with practical applicability.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

6. Poor Integration with Quality Management Systems (QMS)

- QRM is sometimes treated as a standalone process rather than integrated with CAPA, deviation management, change control, and process validation.
- Lack of continuous risk review after initial assessment — risks remain "on paper" but not actively monitored.

7. Regulatory Compliance Pressure

- Different regulatory agencies (FDA, EMA, WHO, PIC/S) may have slightly different expectations for QRM documentation and processes.
- Difficulty in keeping up with evolving guidelines and expectations.
- Fear of audit findings if risk documentation is incomplete or inconsistent.

8. Resource Constraints

- Limited time, manpower, and budget for thorough risk assessment and follow-up.
- Small or medium enterprises may lack dedicated QRM specialists.
- Delays in implementing risk control measures due to resource allocation issues.

9. Inadequate Follow-up and Review

- Risks once identified are not always tracked to ensure mitigation actions are effective.
- Failure to update risk assessments when there are changes in processes, suppliers, or regulatory guidelines.
- No system for periodic review of risk files.

10. Subjectivity in Risk Scoring

- Risk ranking often depends on individual judgment, which can vary widely among team members.
- Differences in perception of severity, occurrence, and detectability.
- Lack of objective criteria leads to inconsistent prioritization.

II. CONCLUSION

Quality Risk Management (QRM) plays a critical role in safeguarding product quality, ensuring patient safety, and maintaining compliance with global regulatory requirements. Despite its importance, many organizations face persistent challenges in effectively implementing QRM. Common barriers include inadequate knowledge and training, inconsistent application across departments, limited availability of reliable data, and over-reliance on subjective judgment. Organizational resistance, resource limitations, and poor integration with other Quality Management System (QMS) elements further reduce its effectiveness. Additionally, varying regulatory expectations across agencies create complexity in maintaining compliance.

To overcome these challenges, companies must invest in building a strong QRM culture supported by top management. Standardized procedures, cross-functional training, and the use of appropriate risk tools can enhance consistency and reliability. Effective integration of QRM with processes like deviation management, CAPA, and change control ensures risks are continuously monitored and mitigated. Regular review and updating of risk assessments help in adapting to process changes, technological advancements, and evolving regulatory requirements.

When applied systematically and supported by organizational commitment, QRM can move beyond being a compliance obligation to become a proactive, data-driven decision-making framework that drives process improvement, optimizes resource use, and ultimately ensures sustained product quality and patient trust.

REFERENCES

[1]. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Q9 Quality Risk Management. Geneva: ICH; 2005.

[2]. Vjayakumar R, Vishal G, Raghunandan V, Nitin KU. Quality risk management in Pharmaceutical industry: A review. Int J Pharm Tech Res 2014;6:908-14.

[3]. International Conference on Harmonization Guidance for Industry: Q9 Quality Risk Management. ICH; 2006.

[4]. U.S Food and Drug Administration. Pharmaceutical CGMPS for the 21st Century-A Risk Based Approach. Rockville, MD: Food and Drug Administration; 2004.

[5]. Food and Drug Administration. Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations: Rockville, MD: Food and Drug Administration; 2006.

[6]. International Conference Harmonization. Pharmaceutical Quality System. ICH Harmonized Tripartite Guideline. Q10. Geneva, Switzerland: U.S. Department of Health and Human; 2008.

[7]. Lotlikar MV. Quality risk management (QRM): A review. J Drug Deliv Ther 2013;3:149-54.

[8]. ICH. Harmonized Tripartite Guideline. Development and Manufacture of Drug Substances (Chemic al Entities and Biotechnological/Biological Entities). Draft Consensus Guideline Q11; 2011.

[9]. ISO; 2000, Application of Risk Management to Medical Devices, ISO 14971; 2000. Available from: http://www.iso.org. [Last accessed on 2018 Dec].

[10]. WHO Guideline on Quality Risk Management A Draft Guidance; 2010.

[11]. Hargreaves, P. (2007). “Good Manufacturing Practice in the Control of Contamination” in Deyner, S.P. and Baird, R.M. (eds.), Guide to Microbiological Control in Pharmaceuticals and Medical Devices, 2nd edition, CRC Press, Boca Raton, FL, pp121-142.

[12]. Patel, K. T. and Chotai, N.P., (2008). Pharmaceutical GMP: Past, Present, and Future--a Re view. Pharmazie.;63(4):251-5.

[13]. Todd, J. I. (2007). Good Manufacturing Practice for Immunological Veterinary Medicinal Prod ucts. Rev Sci Tech.;26(1):135-45.

[14]. Snell JJ, Brown DF, Roberts C, editors. Quality assurance: principles and practice in the microbiology laboratory. Public Health Laboratory Service; 1999. 2.

[15]. EudraLex; The Rules Governing Medicinal Products in the European Union Volume - 4; Good Manufacturing Practices Part I Basic Requirements for Medicinal Products. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/eudralex/vol-4/index_en.htm ,2010

[16]. Mehta Binny, Hemangini Makwana, Pinak Patel, Krunal Detholia. A Concise Review on "Good Documentation Practice". JPSBR .02 March 2019; ISSN NO. 2271-3681, Page No 24.

[17]. Sandle Tim. Good Documentation Practices. Journal of validation Technology. Oct 2014; Volume 20. Page No.1.

[18]. Bhattacharya Joymalya. Good Documentation Practice (Gap): Coordinate Regulatory Requirements in Pharmaceutical Manufacturing Industry. IOSK-JPBS. Sep-Oct 2014; Volume 9. Issue 5 Ver VI. Page No.24.

[19]. Göbel, C., Baier, D., Ruhfus, B. and Hundt, F. (2009). GCP Inspections in Germany and Eu rope Following the Implementation of the Di rective 2001/20/ec, Ger Med Sci. 31;7: doc01. Doi: 10.3205/000060.

[20]. Sandle, T. and Lamba, S. S. (2012). “Effectively Incorporating Quality Risk Management into Quality Systems". in Saghee, M.R..(ed.). Achiev ing Quality and Compliance Excellence in Phar maceuticals: A Master Class GMP Guide, New Delhi: Business Horizons, pp89-128.

[21]. Bolton, F.J. and Howe, S.A. (1999). “Documen tation in the Laboratory” in Snell, J.J.S., Brown, D.F.J., and Roberts, C. Quality Assurance: Prin ciples and Practice in the Microbiology Labora tory, pp19-28.